Clinical Trials in Belfast, United Kingdom

39 recruiting

Showing 120 of 42 trials

Recruiting
Phase 3

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Eosinophilic Asthma
AstraZeneca400 enrolled157 locationsNCT06750289
Recruiting
Phase 3

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled399 locationsNCT06531824
Recruiting
Phase 2

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Heart Failure
Pfizer620 enrolled125 locationsNCT06991257
Recruiting
Phase 3

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
Bayer111 enrolled133 locationsNCT07188805
Recruiting
Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis
Takeda207 enrolled140 locationsNCT06254950
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 2

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Adenocarcinoma, Pancreatic Ductal
Genentech, Inc.260 enrolled89 locationsNCT05968326
Recruiting
Phase 2Phase 3

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

Fabry Disease
Genzyme, a Sanofi Company9,000 enrolled283 locationsNCT00196742
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled187 locationsNCT05894239
Recruiting
Phase 3

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

HER2 MutationAdvanced Non-Small Cell Lung Cancer
Bayer278 enrolled283 locationsNCT06452277
Recruiting
Phase 2

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

Refractory Multiple MyelomaRelapse Multiple Myeloma
Janssen Research & Development, LLC130 enrolled38 locationsNCT06500884
Recruiting
Phase 2Phase 3

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled189 locationsNCT04534205
Recruiting
Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease
Takeda268 enrolled176 locationsNCT06233461
Recruiting
Phase 2

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

Brain TumorGlioblastomaBrain Tumor, Recurrent+1 more
University of Birmingham120 enrolled22 locationsNCT05629702
Recruiting
Phase 1Phase 2

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

Relapsed Neuroblastoma
University of Birmingham160 enrolled23 locationsNCT07334301
Recruiting
Not Applicable

Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy

Breast CancerSentinel Lymph NodeNeoplasm, Breast
University Hospitals of Derby and Burton NHS Foundation Trust1,900 enrolled98 locationsNCT04109079
Recruiting
Phase 1

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Non-small Cell Lung Cancer
University of Leeds200 enrolled14 locationsNCT04550104
Recruiting
Phase 2

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Prostate Cancer
Astellas Pharma Global Development, Inc.900 enrolled241 locationsNCT02960022
Recruiting
Phase 1Phase 2

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom78 enrolled4 locationsNCT07002320